Jammu and Kashmir bans three toxic cough syrups after child deaths in India, intensifies inspections, and urges strict drug safety enforcement
The recent tragedy surrounding the deaths of children linked to toxic cough syrups has once again exposed critical vulnerabilities in India’s pharmaceutical safety mechanisms, with Jammu and Kashmir moving swiftly to prevent a similar catastrophe in the Union Territory. Following the identification of three syrups, Coldrif, Respifresh TR, and Relife, contaminated with diethylene glycol (DEG), a chemical known to cause kidney failure and multi-organ damage, the Jammu and Kashmir Drug and Food Control Organisation (DFCO) banned their sale, distribution, and use. While these products have not been reported in Jammu and Kashmir, past incidents, including the 2020 Udhampur tragedy, underscore the region’s susceptibility to substandard medicines.
With at least 17 child deaths in Madhya Pradesh and Rajasthan, authorities nationwide have undertaken recalls, suspensions, and investigations. In Jammu and Kashmir, over 500 medical shops have been inspected, with no tainted stock recovered, but authorities stress vigilance in pharmacies and hospitals. The Health Department has also advised caution in prescribing cough and cold syrups for children under two, noting most ailments are self-limiting.
The systemic lapses extend beyond isolated negligence. Fragmented state-level probes, inadequate regulatory oversight, unregulated markets, and limited public awareness create fertile ground for unsafe drugs to reach consumers. Medical experts warn that even a single contaminated batch can be deadly in regions with limited laboratory and clinical monitoring.
National attention has turned to judicial oversight, with a PIL filed in the Supreme Court urging a unified, court-monitored investigation, the transfer of pending cases to the CBI, and the establishment of an expert committee under a retired Supreme Court judge. The petition highlights the need for uniformity, transparency, and toxicological testing through accredited laboratories before any drug sale or export.
This crisis calls for an urgent overhaul of India’s drug safety framework. Robust inspections, stricter licensing, public awareness campaigns, and coordination between central and state agencies are essential. Jammu and Kashmir’s proactive surveillance and precautionary bans demonstrate a model of responsiveness, but systemic reform is indispensable to ensure that tragedies like Coldrif do not recur, safeguarding children nationwide from preventable pharmaceutical harm.
